Characterization of the cytosol androgen receptor of the human prostate

Direct measurement of the binding of endogenous androgens to the androgen receptor of human tissues has not been possible because of contamination of tissue with traces of plasma proteins, such as testosterone-binding globulin (TeBG), that contain more androgen-binding capacity than does the receptor itself. Molybdate is known to stabilize the 8–9S forms of other steroid hormone receptors. We took advantage of this phenomenon tocharacterize the androgen receptor of hyperplastic prostates removed at surgery, using sucrose density gradient centrifugation in a vertical rotor. In 10 mM sodium molybdate, theandrogen receptor sediments as a distinct 9.2 ± 0.5S moiety, easily separable from TeBG. Unlike TeBG, the 9S receptor is not removed by absorption with Concanavalin A. [³H]Dihydrotestosterone (³H-labeled 17β-hydroxy-5α-androstan- 3-one) bindingto the 9S receptor is not competed for by excess triamcinoloneacetonide (9α-fluoro-llβ,16α,17α,21-tetrahydroxypregna- l,4-diene-3,20-dione cyclic 16,17-acetonide) or promegestone (17,21-dimethyl-19-non-pregna-4,9-diene-3,20- dione), which are known to bind to the progestin receptor. In contrast, [³H]methyltrienolone (³H-labeled 17β-hydroxy-17αmethyl- estra-4,9, ll-trien-3-one) binds to both androgen and progestin receptors, and consequently, the binding of this ligand to the androgen receptor was assessed in the presence of a 500-fold excess of triamcinolone acetonide. The amounts of 9S binding (7.8 and 5.8 fmol/mg protein) are similar for dihydrotestosterone and methyltrienolone. The amount of 9S binding of testosterone to thereceptor was also similar to that of dihydrotestosterone, but the affinity of testosterone for the 9S receptor was only a fifth or less of that for dihydrotestosterone. The observation that testosterone binds less avidly than dihydrotestosterone to the receptor may explain the role of dihydrotestosterone formation in androgen physiology.